Email discussing FDA approval of pricey cholesterol‑lowering shot (Praluent)

Email discussing FDA approval of pricey cholesterol‑lowering shot (Praluent) The passage merely references a publicly announced FDA drug approval and a casual email exchange. It contains no new allegations, financial flows, or links to high‑level officials, and offers no actionable investigative leads. Key insights: FDA approved Praluent, a costly injectable cholesterol drug.; Email sender Jeffrey E. confirms the drug requires a shot and lacks long‑term safety data.; Forbes article by Matthew Herper cited as source.